Lack of news leaves Lundbeck high and dry

Lundbeck has not had much news to report recently, and several analysts are struggling to pinpoint what is needed in the short term to give the Danish pharmaceutical company wind in its sails on the stock exchange.

Photo: Gregers Tycho/ERH

You might need a flashlight to make out what is keeping Lundbeck afloat at the moment.

The pharmaceutical company's pipeline of future drug candidates remains all but empty, and potential acquisitions have, by the looks of things, been paused.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs